Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy Participants
Interventions: Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Airway Control
Interventions: Not listed
Lead sponsor: Vidacare Corporation; Industry
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Corpus Christi, Texas • El Paso, Texas

Conditions: Eating Disorders
Interventions: GE MR Scanner; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Genetic Conditions, Genetic Disorders
Interventions: RNA sequencing; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson's Disease
Interventions: CVT-301, LIP, Placebo; Drug · Other
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 11
States / cities: Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more

Conditions: Healthy Participants
Interventions: Casdatifan; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Solid Tumors
Interventions: Savolitinib, Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cerebrovascular Accident
Interventions: Music Glove, Conventional Hand Exercise Program; Device · Other
Lead sponsor: David Reinkensmeyer; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Irvine, California

Conditions: Cystic Fibrosis
Interventions: VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more

Conditions: Healthy Volunteers
Interventions: Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB, Period 2 - Treatment Sequence AC; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteer
Interventions: BIIB142, BIIB142-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Peripheral Artery Disease
Interventions: VM202, Placebo; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 55 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obstructive Sleep Apnea, Healthy Subjects
Interventions: Placebo, Lemborexant 10 mg, Lemborexant 25 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 11
States / cities: Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more

Conditions: Cancer
Interventions: GSK2118436 75 mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more

Conditions: Cutaneous Lymphoma, Other Skin Disorders, Mycosis Fungoides, Cutaneous T-cell Lymphoma
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Treatment for Bipolar I Disorder
Interventions: Quetiapine Fumarate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type2 Diabetes
Interventions: High Intensity Body-weight Circuit Training (HIBC); Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 45 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Bacterial Infections
Interventions: VNRX-5133, VNRX-5022, Metronidazole, Placebo; Drug
Lead sponsor: Venatorx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Hearing Loss, Bilateral
Interventions: Parent-Mediated Intervention (PMI); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 5 Years to 8 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Central Nervous System
Interventions: NIH Toolbox Cognitive Battery; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parenteral Nutrition
Interventions: Sodium Glycerophosphate Injection, Sodium Phosphates Injection; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension
Interventions: Partial sleep deprivation (sleep restriction), Normal sleep; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 35 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

Observational Study of Rapid Sequence Intubation Drug Delivery Using Intraosseous and Intravenous Access.

AN/BN Risk Factors Study

RNA to the RESCUE: Evaluation to Assess the Clinical Utility of RNA Sequencing in Establishing a Genetic Diagnosis or Adjudicating a Previously Established Genetic Diagnosis.

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

To Determine the Therapeutic Effect of the Music Glove and Conventional Hand Exercises to Subacute Stroke Patients

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

Hepatocyte Growth Factor to Improve Functioning in PAD

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

High Intensity Body-weight Circuit Training in Type 2 Diabetics

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

Long-Term Outcomes of Early Communication Intervention for Deaf/Hard of Hearing Toddlers

Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

Sleep Restriction and Parental History of Hypertension